China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $1.58M invested in China SXT Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
11% less capital invested
Capital invested by funds: $1.77M → $1.58M (-$191K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $1.2M | – | – | – |
|
2
Renaissance Technologies
New York
| $335K | – | – | – |
|
3
Citadel Advisors
Miami,
Florida
| $14K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $11K | – | – | – |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $10K | – | – | – |
|
|
BWA
6
Beam Wealth Advisors
Covington,
Louisiana
| $10K | – | – | – |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$7K | – | – |
|
SXTC Hedge Fund Activity: Q1 2020 in Review
1 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2020, worth a combined $1.58M — down 11% from $1.77M a quarter earlier.
Fund positioning in SXTC was balanced in Q1 2020: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Deutsche Bank, cutting an estimated $7K.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $1.58M of China SXT Pharmaceuticals stock for Q1 2020, down 11% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q1 2020 and 0 closed out.
- The largest China SXT Pharmaceuticals seller in Q1 2020 was Deutsche Bank, an estimated $7K sold.
Based on aggregated 13F filings for Q1 2020.